Recently, Shanghai Easy-Flow Medical Tech Co., Ltd. ("Easy-Flow™") has achieved a significant milestone in its international expansion strategy with the ANVISA approval of its innovative EF-OptiPrep™ Constrained PTA Dilatation Balloon Catheter in Brazil. This marks the company's first successful international product registration, demonstrating its commitment to bringing advanced medical solutions to global markets.

EF-OptiPrep™Constrained PTA Dilatation Balloon Catheter is intended for balloon dilatation of lesions in the peripheral vasculature, including the iliac, femoral, ilio-femoral, popliteal, infra-popliteal and renal arteries.

Clinical studies reveal that flow-limiting dissections occur in up to 42% of lower extremity percutaneous transluminal angioplasty (PTA) procedures. Severe dissections frequently necessitate stent implantation, adversely impacting patients' long-term outcomes.To address this challenge, controlled dilation technology has emerged as an innovative vessel preparation strategy. EF-OptiPrep™ integrates a nitinol constraint structure that uniformly encases the balloon. Upon inflation, this design creates a patterned surface of alternating pillows and grooves, ensuring even dilation.The grooves serve as low-pressure zones, mitigating excessive vessel wall stress and reducing intimal trauma. This mechanism significantly lowers the incidence of flow-limiting dissections and decreases reliance on bailout stenting. By optimizing vessel preparation, EF-OptiPrep™ enhances the foundation for subsequent therapies, such as drug-coated balloon (DCB) treatment, improving procedural success and long-term patency.

EF-OptiPrep™ received Chinese market approval in December 2023 and has since been swiftly adopted across multiple clinical centers nationwide. Its reliable performance and outstanding clinical outcomes have garnered widespread recognition from physicians. Brazil's robust healthcare infrastructure and substantial patient population make it an ideal entry point for global expansion. The ANVISA approval not only validates the product's quality and efficacy but also paves the way for Easy-Flow™'s expansion across Latin America and beyond guided by its dual-market strategy, Easy-Flow™ is accelerating clinical adoption in China to meet real-world patient needs while proactively pursuing global registrations. With a vision for international expansion, Easy-Flow™ will first establish its presence in Brazil as a strategic gateway, then extend its reach to additional global markets – delivering high-quality medical solutions to patients worldwide.

*Fujihara M, Takahara M, Sasaki S, et al. Journal of endovascular therapy, 2017, 24(3): 367-375.